PE-22-28 (8mg) · Research brief

PE-22-28 Peptide: Mechanism, Effects and Availability

Real Peptides Research TeamEditorial

Updated September 22, 20268 min read

56 WORDS

Short answer

Most research peptides that get attention act on growth hormone, tissue repair, or metabolism. PE-22-28 does none of those things. It's a seven-amino-acid fragment aimed at a potassium channel in the brain, and it exists for one blunt reason: the longer peptide it was carved from fell apart in plasma far too quickly to study properly.

Key takeaways

PE-22-28 is a seven-amino-acid shortened analog of spadin, itself derived from the propeptide of the sortilin receptor.
The molecular target is TREK-1 (KCNK2), a two-pore-domain background potassium channel whose blockade increases excitability of serotonergic neurons in rodent models.
No human clinical trials, pharmacokinetic studies, or toxicology reports have been published for PE-22-28, so any stated side effect list is extrapolation rather than data.
The numbers in PE-22-28 are residue coordinates within the sortilin propeptide, not a product code, which is why PE 23-28 and PE 24-28 exist as related analogs.
An 8mg PE-22-28 vial states lyophilised mass only; net peptide content and purity come from the certificate of analysis, not the label.
PE-22-28 is not approved by any regulator for any indication and is supplied exclusively for in vitro and laboratory research.

We supply research-grade compounds to laboratories, and PE-22-28 generates more confused questions than almost anything else on the neuro side of the catalogue. Roughly half of those questions are about side effects that have never been formally characterised in people. The other half are about what an 8mg vial label actually means.

What is PE-22-28?

PE-22-28 is a seven-amino-acid peptide derived from the propeptide of sortilin and designed as a shortened analog of spadin. In rodent research it acts as an inhibitor of TREK-1, a two-pore-domain potassium channel encoded by the KCNK2 gene and linked to mood regulation. It is supplied strictly for laboratory research and is not an approved drug.

The common over-simplification is that PE-22-28 is just 'smaller spadin' behaving identically. It isn't. Truncating the sequence changed both the reported channel-blocking potency and the metabolic stability profile, which is the entire reason the shortened analogs were synthesised. What follows covers the TREK-1 mechanism, what the rodent work actually reported, the honest state of PE-22-28 side effect data, and how to read an 8mg vial specification before you buy anything.

From sortilin to spadin to a seven-residue fragment

PE-22-28 traces back to a single protein: sortilin, a sorting receptor also known as neurotensin receptor-3. When the enzyme furin cleaves pro-sortilin into its mature form, it releases a propeptide. Researchers at the Institut de Pharmacologie Moléculaire et Cellulaire in France found that a 17-residue stretch of that propeptide, which they named spadin, blocked TREK-1 channels and produced antidepressant-like behaviour in mice. That finding was published in PLoS Biology in 2010.

TREK-1 (also written K2P2.1) is a background potassium channel. When it's open, potassium leaks out of the neuron, holding the membrane at a more negative potential and making the cell harder to fire. Mice genetically lacking TREK-1 show a depression-resistant phenotype, reported by the same research group in Nature Neuroscience. Block the channel and you remove a brake on serotonergic neurons in the dorsal raphe nucleus.

So why PE-22-28 rather than spadin itself? Spadin degrades rapidly in blood, which caps how far a 17-residue peptide can be pushed in vivo. Djillani and colleagues published shortened spadin analogs in Frontiers in Pharmacology in 2017, reporting that the seven-residue version, PE-22-28, inhibited TREK-1 more effectively than the parent peptide while surviving longer in circulation. PE-22-28 is not a reinvention of spadin's mechanism. It's the same target, reached with less molecule.

In our experience fielding supplier enquiries, this origin story is the part almost every product listing for PE-22-28 leaves out entirely.

What the rodent studies report, and what they don't

Here's the detail most descriptions get wrong: the name is a coordinate, not a code. PE refers to the sortilin propeptide, and 22-28 are the residue positions the fragment spans within that propeptide. Spadin is PE 12-28. So PE-22-28 is literally the final seven residues of spadin, nothing more exotic than that. Once you see the naming logic, the sibling analogs (PE 23-28, PE 24-28) make immediate sense as a structure-activity series rather than separate inventions.

The published rodent work reports that shortened spadin analogs reduced immobility in standard behavioural despair paradigms such as the forced swim and tail suspension tests, and that effects appeared over a shorter treatment window than classical SSRIs typically require in the same models. Research also reports increases in markers of hippocampal neurogenesis and synaptogenesis, alongside involvement of the mTOR signalling pathway, which is the same broad territory studied in fast-acting antidepressant research.

What that literature does not contain: human clinical trials, published human pharmacokinetics, chronic toxicology, or any established dosing framework. Rodent despair models are screening tools. They flag compounds worth investigating further; they don't forecast human outcomes. Anyone presenting PE-22-28 as a validated antidepressant is describing a mouse result as though it were a clinical one.

We mean this sincerely: the distance between 'active in rodents' and 'useful in humans' is exactly where most promising neuro peptides, including several with better funding than PE-22-28, quietly stop.

Side effects, open questions, and what an 8mg vial tells you

There is no published human side effect profile for PE-22-28. That's the honest answer to the most-searched question about this compound, and any source presenting a tolerability list is extrapolating from animals. Rodent studies of spadin and its shortened analogs reported no gross behavioural toxicity at the quantities tested, and the original research group specifically noted that spadin did not appear to compromise the neuroprotective or seizure-threshold roles TREK-1 also plays. That's encouraging for a screening study. It is not a safety dataset.

The mechanistic caution worth understanding is this: TREK-1 isn't only a mood channel. It participates in neuroprotection during cerebral ischaemia, in pain signalling, and in the response to volatile anaesthetics, all documented in the TREK-1 knockout literature from the same French laboratory. A systemic channel blocker doesn't get to choose which tissue it acts on. That pleiotropy is the real basis for every serious question about PE-22-28 side effects, and it's a large part of why the compound stays research-use-only.

On the label: 8mg describes the mass of lyophilised peptide in the vial. It is not a concentration and it is not an instruction. Net peptide content can differ from gross vial weight because lyophilised material carries counter-ions and residual water, which is why a certificate of analysis showing HPLC purity and mass spectrometry identity confirmation matters more than the number printed on the cap. Everything here is research education. PE-22-28 is supplied for laboratory use only, and if a question about an animal's health brought you here, talk to your veterinarian, because PE-22-28 is not a veterinary product and is not intended for human or animal consumption.

Most people evaluating PE-22-28 are really weighing it against spadin or against a reference antidepressant used in the same rodent models. This table summarises what the published literature reports for each, with no efficacy claims attached.

Compound	Origin and length	Reported TREK-1 activity	Stability and handling	Bottom line for lab use
Spadin (PE 12-28)	17 residues cleaved from the sortilin propeptide	The original proof of concept for TREK-1 blockade as an antidepressant mechanism	Reported rapid degradation in plasma, limiting the usable in vivo window	Historically the reference compound, but fragile enough that it drove the search for analogs
PE-22-28	7 residues, the terminal fragment of spadin	Reported stronger TREK-1 inhibition than the parent peptide in the 2017 Frontiers in Pharmacology work	Reported improved in vivo stability; supplied lyophilised and requiring cold storage	The most studied shortened analog and the one laboratories request most often
PE 23-28 and PE 24-28	6 and 5 residues respectively	Activity reported at these shorter lengths, with differences between analogs	Comparable lyophilised handling to the seven-residue form	Useful for structure-activity comparison, but with a far thinner dataset than PE-22-28
Fluoxetine (SSRI reference)	Small molecule serotonin reuptake inhibitor	Not a TREK-1 blocker; acts on the serotonin transporter	Shelf-stable, fully characterised, decades of clinical data	The benchmark rodent studies compare against, not a peptide substitute

What If: Common Research Handling Scenarios

What if the vial looks empty when it arrives?

Hold it to the light before assuming anything is missing. An 8mg lyophilisation of PE-22-28 frequently forms a thin translucent film or a small puck at the base rather than a visible mound of powder, and shipping vibration can spread that film across the vial wall where it becomes almost invisible. Cross-check the vial against the batch certificate of analysis, which states the gross fill weight for that lot. If the certificate matches the labelled fill, the material is present. Photograph the vial on receipt regardless, because documentation at intake resolves supplier disputes far faster than recollection does.

What if there is no certificate of analysis for the batch?

Treat an uncertified vial as an unidentified compound and don't put it into an experiment. A genuine certificate for PE-22-28 pairs an HPLC chromatogram establishing purity with a mass spectrometry trace confirming molecular weight against the expected seven-residue sequence. Without both, you have a white powder and a claim. Batch-specific documentation also matters more here than with better-known peptides, because the shortened spadin analogs are structurally similar to each other and a sequence error of one residue produces PE 23-28, not PE-22-28, with no visual difference whatsoever.

What if reconstituted material sat at room temperature overnight?

Document the excursion, note it against the experiment, and assume potency is compromised rather than intact. Peptides in aqueous solution are vulnerable to hydrolysis and microbial growth in a way lyophilised powder is not, and short sequences give degradation products that no bench-level visual inspection will reveal. Cloudiness or precipitate is a clear fail signal, but clear solution is not a pass signal. There is no reliable at-home or in-lab shortcut for verifying that reconstituted PE-22-28 retains its original structure short of re-running analytical chemistry on it.

What if a supplier lists dosing information alongside the product?

Treat it as a regulatory red flag about the supplier rather than useful information about the compound. PE-22-28 has no established human dosing framework because no human study has been published, so any suggested schedule is invented. Legitimate research suppliers state mass, purity, sequence, and storage conditions, then stop. A vendor willing to fabricate a protocol is a vendor with an elastic relationship to accuracy in other areas too, including the analytical data on their certificates.

The honest state of the evidence

Let's be direct about this: PE-22-28 is an interesting rodent result and, right now, nothing more than that. The TREK-1 hypothesis is legitimate, the French work behind it is serious pharmacology, and the mechanism is genuinely distinct from monoamine reuptake drugs. But there are no human trials, no approved formulation, no characterised safety profile, and no regulator anywhere has evaluated PE-22-28 for any purpose. Treating a seven-residue research peptide as a self-directed intervention because a mouse swam longer in a beaker isn't a calculated risk. It's a guess wearing a mechanism as a costume.

Batch documentation for every compound we synthesise is published on our certificates of analysis page, the full research catalogue sits in the shop, and facility and shipping details are on our location page. If TREK-1 work forms part of a wider neuro-research programme, related compounds such as Selank Liquid Spray are synthesised to the same small-batch purity standard.

PE-22-28 is one of the clearest examples in peptide research of a compound whose story is mostly chemistry rather than outcome. Someone looked at a 17-residue peptide that worked in mice and disintegrated in plasma, cut it down to its last seven residues, and got something that blocked the channel harder and lasted longer. That's a real medicinal chemistry achievement. It is also, at this moment, the whole achievement. The channel it blocks remains a hypothesis about depression, and hypotheses don't become therapies until humans are studied, which hasn't happened yet.

Questions

PE-22-28 acts as an inhibitor of TREK-1, a two-pore-domain background potassium channel encoded by the KCNK2 gene. Blocking that channel reduces potassium leak from the neuron, which in rodent studies increases excitability of serotonergic neurons in the dorsal raphe nucleus. The mechanism is entirely separate from serotonin reuptake inhibition, which is what makes the TREK-1 target interesting to researchers.

There is no published human side effect profile for PE-22-28, because no human clinical trials have been conducted. Rodent studies of spadin and its shortened analogs reported no gross behavioural toxicity at the quantities tested, but that is screening data, not a safety dataset. The mechanistic concern researchers discuss is that TREK-1 also participates in neuroprotection during ischaemia, pain signalling, and anaesthetic response, so systemic blockade is not target-isolated.

Spadin is a 17-amino-acid peptide from the sortilin propeptide spanning residues 12 to 28, while PE-22-28 is the terminal seven residues of that same sequence. The 2017 Frontiers in Pharmacology work from the French group that discovered spadin reported that the shortened form inhibited TREK-1 more effectively and survived longer in circulation. Same target, shorter chain, better reported stability.

No. PE-22-28 has not been approved by the FDA or any other regulator for any indication, and it has not entered published human clinical trials. It is classified and supplied as a research chemical for laboratory use only, which is a fundamentally different regulatory category from an investigational or approved drug.

The 8mg figure refers to the mass of lyophilised peptide in the vial, not a concentration and not a usage quantity. Net peptide content can be lower than gross vial weight because lyophilised material retains counter-ions and residual moisture. The certificate of analysis for that specific batch, showing HPLC purity and mass spectrometry identity, is the document that tells you what the vial genuinely holds.

Both are variations of the same compound name. PE refers to the sortilin propeptide and 22-28 are the residue positions the fragment spans, so hyphenation is inconsistent across suppliers and papers. Peptid is simply the non-English spelling of peptide appearing in translated listings. None of these variants indicate a different molecule, but the sequence on the certificate of analysis is what confirms identity.

No published human study of PE-22-28 exists in the peer-reviewed literature. The evidence base consists of in vitro electrophysiology on TREK-1 channels and rodent behavioural work, primarily from the Institut de Pharmacologie Moléculaire et Cellulaire group that originally identified spadin. Behavioural despair models in mice are screening tools and do not predict human clinical outcomes.

PE-22-28 is sold to researchers and laboratories for in vitro and non-clinical research use only, and suppliers offering PE-22-28 for sale are obliged to state that restriction clearly. It is not a consumer product, not a supplement, and not a veterinary product. Any listing that pairs it with human usage guidance is operating outside the research-use-only framework.

Lyophilised PE-22-28 is stored frozen and protected from light and moisture, following the storage conditions stated on the batch certificate of analysis. Once in aqueous solution, peptides become vulnerable to hydrolysis and microbial growth, so reconstituted material is handled cold and treated as time-limited. A clear solution is not evidence of an intact peptide, since degradation is invisible without analytical testing.

A useful certificate pairs an HPLC chromatogram quantifying purity with a mass spectrometry result confirming the molecular weight matches the expected seven-residue sequence. Purity alone is insufficient for the spadin analog family, because PE 23-28 and PE 24-28 are chemically similar and a single-residue synthesis error would still chromatograph cleanly. Identity confirmation is the check that separates PE-22-28 from its near neighbours.

No. Antidepressants are approved drugs with characterised human pharmacology, whereas PE-22-28 is a research peptide with rodent behavioural data and no clinical evaluation. SSRIs such as fluoxetine act on the serotonin transporter, while PE-22-28 targets a potassium channel, so the two are not interchangeable even at the level of mechanism.

Spadin degrades rapidly in blood, which constrained how usefully the 17-residue peptide could be studied in living animals. The shortened analog series was synthesised to address that stability ceiling, and the published 2017 work reported that the seven-residue PE-22-28 both inhibited TREK-1 more effectively and persisted longer in circulation than the parent compound.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA